Cargando…

A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma?

Detalles Bibliográficos
Autores principales:	Lombardi, Giuseppe, Idbaih, Ahmed, Le Rhun, Emilie, Preusser, Matthias, Zagonel, Vittorina, French, Pim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765319/ https://www.ncbi.nlm.nih.gov/pubmed/33333830 http://dx.doi.org/10.3390/cancers12123775

Ejemplares similares

Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
por: Birzu, Cristina, et al.
Publicado: (2020)

How we treat glioblastoma
por: Weller, Michael, et al.
Publicado: (2019)

The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study
por: Lombardi, Giuseppe, et al.
Publicado: (2021)

Recurrent Glioblastoma: What Is the Route?
por: Bosio, Alberto, et al.
Publicado: (2023)

Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study
por: Parrozzani, Raffaele, et al.
Publicado: (2020)

Sustained Accumulation of Blood-Derived Macrophages in the Immune Microenvironment of Patients with Recurrent Glioblastoma after Therapy
por: Magri, Sara, et al.
Publicado: (2021)

Validation of the Comprehensive Geriatric Assessment as a Predictor of Mortality in Elderly Glioblastoma Patients
por: Lombardi, Giuseppe, et al.
Publicado: (2019)

Gliomas
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

Urine 2-Hydroxyglutarate in Glioma
por: Lombardi, Giuseppe, et al.
Publicado: (2016)

Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview
por: Lombardi, Giuseppe, et al.
Publicado: (2022)

Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study
por: Parrozzani, Raffaele, et al.
Publicado: (2020)

PET/MR in recurrent glioblastoma patients treated with regorafenib: [(18)F]FET and DWI-ADC for response assessment and survival prediction
por: Lombardi, Giuseppe, et al.
Publicado: (2022)

Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma
por: Seystahl, Katharina, et al.
Publicado: (2022)

Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)
por: Padovan, Marta, et al.
Publicado: (2021)

Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study
por: Brandes, Alba A., et al.
Publicado: (2017)

Treatment of Malignant Gliomas in Elderly Patients: A Concise Overview of the Literature
por: Farina, Patrizia, et al.
Publicado: (2014)

Magnetic Resonance Imaging Correlates of Immune Microenvironment in Glioblastoma
por: Salvalaggio, Alessandro, et al.
Publicado: (2022)

How we treat patients with leptomeningeal metastases
por: Le Rhun, Emilie, et al.
Publicado: (2019)

ACT-26 ABT-414 (DEPATUX-M) IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: WHERE DO WE STAND?
por: Preusser, Matthias
Publicado: (2019)

Seizures, Edema, Thrombosis, and Hemorrhages: An Update Review on the Medical Management of Gliomas
por: Zoccarato, Marco, et al.
Publicado: (2021)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

The examination of geriatric pharmacotherapy
por: Farinde, Abimbola
Publicado: (2013)

Non-Compliance in Pharmacotherapy
por: Reddy, M. S.
Publicado: (2012)

Introducing a new ESMO Open article series: how I treat side effects of immunotherapy
por: Preusser, Matthias
Publicado: (2019)

The role of radiation therapy and systemic treatments in meningioma: The present and the future
por: Caccese, Mario, et al.
Publicado: (2023)

An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

Pharmacotherapy of pediatric metabolic syndrome
por: Kelishadi, Roya, et al.
Publicado: (2013)

Obesity Treatment – Is Pharmacotherapy the Answer?
por: Rangbulla, Aditya Kumar
Publicado: (2020)

Potential pharmacotherapy for Zinner syndrome
por: Takeshima, Teppei
Publicado: (2023)

Caring for Patients with Advanced Stage Cancer at the Time of COVID‐19
por: Brunello, Antonella, et al.
Publicado: (2020)

Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study
por: Olioso, Debora, et al.
Publicado: (2021)

Patterns of gray and white matter functional networks involvement in glioblastoma patients: indirect mapping from clinical MRI scans
por: Sansone, Giulio, et al.
Publicado: (2023)

Interferon-β sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02
por: Lohmann, Birthe, et al.
Publicado: (2020)

A new concept in NF2 pharmacotherapy: targeting fatty acid synthesis
por: Stepanova, Dina S., et al.
Publicado: (2018)

Pharmacotherapy for Age-Related Macular Degeneration
por: Ahmadieh, Hamid
Publicado: (2008)

Pharmacotherapy during Pregnancy, Childbirth, and Lactation
por: Allegaert, Karel
Publicado: (2022)

Venous thromboembolic events in glioblastoma patients: An epidemiological study
por: Eisele, Amanda, et al.
Publicado: (2022)

The evolving landscape in advanced penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2015)

40. AN UPDATE ON THE DEVELOPMENT OF A NEW TOOL TO ASSESS RESPONSE IN LEPTOMENINGEAL METASTASIS
por: Weller, Michael, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_171mqfeuvb5t3aiillp6p5d7d0